Altered proteome profiles have been reported in both postmortem brain tissues and body fluids of subjects with Alzheimer disease (AD), but their broad relationships with AD pathology, amyloid pathology, and tau-related neurodegeneration have not yet been fully explored. Using a robust automated MS-based proteomic biomarker discovery workflow, we measured cerebrospinal fluid (CSF) proteomes to explore their association with well-established markers of core AD pathology. Cross-sectional analysis was performed on CSF collected from 120 older community-dwelling adults with normal (n = 48) or impaired cognition (n = 72). LC-MS quantified hundreds of proteins in the CSF. CSF concentrations of β-amyloid 1-42 (Aβ <sub>1-42</sub> ), tau,...
Introduction: Alzheimer’s disease (AD) is a neurodegenerative disease affecting the brain. Today the...
The fact that cerebrospinal fluid (CSF) deeply irrigates the brain together with the relative simpli...
Development of disease-modifying therapies against Alzheimer’s disease (AD) requires biomarkers refl...
Altered proteome profiles have been reported in both postmortem brain tissues and body fluids of sub...
Abstract Background Altered proteome profiles have been reported in both postmortem brain tissues an...
Neurodegenerative diseases are a growing burden, and there is an urgent need for better biomarkers f...
BACKGROUND: Increased knowledge of the evolution of molecular changes in neurodegenerative disorders...
Although neuropsychiatric symptoms (NPS) are common and severely affect older people with cognitive ...
Alzheimer’s disease (AD) pathology develops many years before the onset of cognitive symptoms. Two p...
Alzheimer’s disease (AD) is the most common cause of dementia and is characterized by aggregation of...
Alzheimer\u27s disease (AD) pathology develops many years before the onset of cognitive symptoms. Tw...
AbstractIntroductionThe dynamic range of cerebrospinal fluid (CSF) amyloid β (Aβ1–42) measurement do...
Clinical diagnosis of Alzheimer's disease (AD) relying on symptomatic features has a low specificity...
<div><p>Disease modifying treatments for Alzheimer’s disease (AD) constitute a major goal in medicin...
In the diagnosis of Alzheimer\u2019s disease (AD) total tau (T-tau), tau phosphorylated at threonine...
Introduction: Alzheimer’s disease (AD) is a neurodegenerative disease affecting the brain. Today the...
The fact that cerebrospinal fluid (CSF) deeply irrigates the brain together with the relative simpli...
Development of disease-modifying therapies against Alzheimer’s disease (AD) requires biomarkers refl...
Altered proteome profiles have been reported in both postmortem brain tissues and body fluids of sub...
Abstract Background Altered proteome profiles have been reported in both postmortem brain tissues an...
Neurodegenerative diseases are a growing burden, and there is an urgent need for better biomarkers f...
BACKGROUND: Increased knowledge of the evolution of molecular changes in neurodegenerative disorders...
Although neuropsychiatric symptoms (NPS) are common and severely affect older people with cognitive ...
Alzheimer’s disease (AD) pathology develops many years before the onset of cognitive symptoms. Two p...
Alzheimer’s disease (AD) is the most common cause of dementia and is characterized by aggregation of...
Alzheimer\u27s disease (AD) pathology develops many years before the onset of cognitive symptoms. Tw...
AbstractIntroductionThe dynamic range of cerebrospinal fluid (CSF) amyloid β (Aβ1–42) measurement do...
Clinical diagnosis of Alzheimer's disease (AD) relying on symptomatic features has a low specificity...
<div><p>Disease modifying treatments for Alzheimer’s disease (AD) constitute a major goal in medicin...
In the diagnosis of Alzheimer\u2019s disease (AD) total tau (T-tau), tau phosphorylated at threonine...
Introduction: Alzheimer’s disease (AD) is a neurodegenerative disease affecting the brain. Today the...
The fact that cerebrospinal fluid (CSF) deeply irrigates the brain together with the relative simpli...
Development of disease-modifying therapies against Alzheimer’s disease (AD) requires biomarkers refl...